Pacific Biosciences And Invitae Agree To Develop Ultra-High-Throughput Clinical Whole Genome Sequencing Platform

Pacific Biosciences And Invitae Agree To Develop Ultra-High-Throughput Clinical Whole Genome Sequencing Platform

Pacific Biosciences today announced a multi-year collaboration with Invitae Corporation to begin development of a production-scale high-throughput sequencing platform. Identifying the many underlying genetic influences on human health is emerging as a tool for evaluating overall clinical care and prognosis. Whole genome sequencing offers the most comprehensive view of medically relevant genetic variations. PacBio cites … Read more

Synthetic Biologics Targets The Microbiome For GI Therapies

Synthetic Biologics Targets The Microbiome For GI Therapies

Synthetic Biologics, Inc is clinical-stage company leveraging the microbiome to develop therapeutics designed to treat gastrointestinal (GI) diseases. The Company’s lead clinical development candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), … Read more

This Clinical Trial Will Test A Combination Monoclonal Antibody Therapy For Mild/moderate COVID-19

This Clinical Trial Will Test A Combination Monoclonal Antibody Therapy For Mild/moderate COVID-19

People who have mild or moderate COVID-19 could benefit from the results of a Phase 2/3 safety and efficacy clinical trial to evaluate a combination investigational monoclonal antibody therapy. The two experimental antibodies, BRII-196 and BRII-198, target SARS-CoV-2, the virus that causes COVID-19. The trial, known as ACTIV-2, is sponsored by the National Institute of … Read more

IPO: Cullinan Oncology, the Risk-managed Portfolio Of Cancer Drugs Startup

IPO: Cullinan Oncology, the Risk-managed Portfolio Of Cancer Drugs Startup

Cullinan Oncology, LLC, a Cambridge, MA-based company, plans to raise about $150 million by offering 8.3 million shares at a price range of $17 to $19. At the midpoint of this range, Cullinan’s market value would be $750 million, fully diluted. The company is focused on developing a diversified pipeline of targeted oncology and immuno-oncology … Read more

Categories IPO

What Is RNA Interference?

What Is RNA Interference?

The human genome is comprised of approximately 22,000 genes, each embodied as a region of deoxyribonucleic acid (DNA) that contains codes for the synthesis of certain proteins. DNA, which consists of building blocks known as “nucleotides,” occurs in the familiar “double helix” shape, with two strands coiled around the same axis. One end of a … Read more

DARPA Dive: Biological Responders For Brain Injury

DARPA Dive: Biological Responders For Brain Injury

The Defense Advanced Research Projects Agency (DARPA), established in 1958, is an agency within the Department of Defense (DOD) responsible for catalyzing the development of technologies that maintain and advance the capabilities and technical superiority of the U.S. military. In short, it’s the way the U.S. military tries to prevent technical surprise. Product Service Code: … Read more

Completed Gene Therapy Trials Tracked By U.S. National Library Of Medicine As Of December 2020

Completed Gene Therapy Trials Tracked By U.S. National Library Of Medicine As Of December 2020

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. In a clinical trial, participants receive specific interventions according to the research plan or protocol created by the investigators. … Read more

Risks With CRISPR Gene Editing

Risks With CRISPR Gene Editing

Scientists studying the effects of the potentially game-changing gene-editing tool CRISPR/Cas9 have found it can cause unexpected genetic damage which could lead to dangerous changes in some cells. The findings, published in the journal Nature Biotechnology in 2018, have safety implications for gene therapies that are being developed using CRISPR/Cas9 – a type of molecular … Read more